search
Back to results

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

Primary Purpose

Preterm Premature Rupture of Membranes

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Magnesium sulfate
Sponsored by
Regional Obstetrical Consultants
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Preterm Premature Rupture of Membranes focused on measuring short term tocolysis, preterm premature rupture of membranes

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • English or Spanish speaking
  • preterm premature rupture of membranes
  • 26 - 32.6 weeks gestation
  • cervical dilation </= 4 cm

Exclusion Criteria:

  • suspected intrauterine or intraamniotic infection
  • > 6 hours of tocolysis prior to admission
  • positive fetal lung maturity

Sites / Locations

  • Regional Obstetrical Consultants

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Magnesium sulfate

Normal saline

Arm Description

x 48 hours IV

x 48 hours IV

Outcomes

Primary Outcome Measures

hours of latency to delivery
from start of study drug to delivery

Secondary Outcome Measures

maternal postpartum length of stay
from start of study drug to delivery
maternal infection rates
from start of study drug to maternal discharge from hospital
neonatal ventilator days
from delivery to 28 days of life
neonatal early onset infection
from delivery to 28 days of life
neonatal length of stay
from delivery to 28 days of life

Full Information

First Posted
April 19, 2007
Last Updated
August 17, 2016
Sponsor
Regional Obstetrical Consultants
search

1. Study Identification

Unique Protocol Identification Number
NCT00463736
Brief Title
Magnesium Sulfate Versus Placebo for Tocolysis in PPROM
Official Title
Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Terminated
Why Stopped
enrollment proceeding too slowly
Study Start Date
April 2007 (undefined)
Primary Completion Date
March 2010 (Actual)
Study Completion Date
March 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Regional Obstetrical Consultants

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.
Detailed Description
The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence. The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM. Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation <4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or > 6 hours tocolysis at time of admission will be excluded. Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Premature Rupture of Membranes
Keywords
short term tocolysis, preterm premature rupture of membranes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Magnesium sulfate
Arm Type
Active Comparator
Arm Description
x 48 hours IV
Arm Title
Normal saline
Arm Type
Placebo Comparator
Arm Description
x 48 hours IV
Intervention Type
Drug
Intervention Name(s)
Magnesium sulfate
Primary Outcome Measure Information:
Title
hours of latency to delivery
Description
from start of study drug to delivery
Time Frame
0 hours to > 168 hours
Secondary Outcome Measure Information:
Title
maternal postpartum length of stay
Description
from start of study drug to delivery
Time Frame
0 hours to > 168 hours
Title
maternal infection rates
Description
from start of study drug to maternal discharge from hospital
Time Frame
0 hours to > 168 hours
Title
neonatal ventilator days
Description
from delivery to 28 days of life
Time Frame
0 to 28 days
Title
neonatal early onset infection
Description
from delivery to 28 days of life
Time Frame
0 to 28 days
Title
neonatal length of stay
Description
from delivery to 28 days of life
Time Frame
0 to 28 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: English or Spanish speaking preterm premature rupture of membranes 26 - 32.6 weeks gestation cervical dilation </= 4 cm Exclusion Criteria: suspected intrauterine or intraamniotic infection > 6 hours of tocolysis prior to admission positive fetal lung maturity
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian M Briery, MD
Organizational Affiliation
Regional Obstetrical Consultants; UT Chattanooga OB-GYN Department
Official's Role
Principal Investigator
Facility Information:
Facility Name
Regional Obstetrical Consultants
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
35947046
Citation
Wilson A, Hodgetts-Morton VA, Marson EJ, Markland AD, Larkai E, Papadopoulou A, Coomarasamy A, Tobias A, Chou D, Oladapo OT, Price MJ, Morris K, Gallos ID. Tocolytics for delaying preterm birth: a network meta-analysis (0924). Cochrane Database Syst Rev. 2022 Aug 10;8(8):CD014978. doi: 10.1002/14651858.CD014978.pub2.
Results Reference
derived

Learn more about this trial

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

We'll reach out to this number within 24 hrs